Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
Christopher R. Cline, the Chief Financial Officer of Travere Therapeutics, Inc. (NASDAQ:TVTX), recently sold 48 shares of the company’s common stock. The transaction, which took place on April 11, 2025, was executed at a price of $13.1446 per share, amounting to a total value of approximately $630. According to InvestingPro data, the stock has shown remarkable strength with a 132.81% return over the past year, despite recent market volatility.
Following this transaction, Cline retains ownership of 89,990 shares of Travere Therapeutics. This sale was conducted to cover tax withholding obligations related to the settlement of vested restricted stock units, as mandated by the company’s equity incentive plans. It was not a discretionary trade by Cline, but rather a "sell to cover" transaction required by the issuer. With a market capitalization of $1.32 billion and analyst price targets ranging from $22 to $47, InvestingPro subscribers can access 10+ additional exclusive insights and a comprehensive Pro Research Report about Travere’s financial health and growth prospects.
In other recent news, Travere Therapeutics reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share of -$0.47, compared to the forecasted -$0.64. The company also exceeded revenue forecasts, reporting $74.79 million against a predicted $71.08 million. Travere has submitted a supplemental New Drug Application to the FDA for FILSPARI, which could become the first approved treatment for focal segmental glomerulosclerosis (FSGS). Analysts from Canaccord Genuity and Citi have expressed optimism about Travere’s prospects, with Canaccord raising the stock target to $47 and Citi increasing its target to $35, both maintaining a Buy rating.
Cantor Fitzgerald also maintained an Overweight rating on Travere, emphasizing the potential market uptake of FILSPARI for FSGS. The company anticipates that the FDA will decide on the acceptance of the sNDA for review in the second quarter of 2025. Travere’s Filspari continues to drive sales growth, with significant year-over-year increases, and the company is preparing for new product launches. The FDA’s decision on FILSPARI’s approval for FSGS treatment will be a significant milestone, as there are currently no FDA-approved pharmacologic therapies available for this condition. These developments reflect Travere’s strategic focus on expanding its presence in the nephrology market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.